New hope for lung cancer patients: drug after standard therapy may delay progression

NCT ID NCT07161388

First seen Nov 01, 2025 · Last updated May 26, 2026 · Updated 24 times

Summary

This study looks at whether the drug durvalumab, given after chemoradiation, can help control limited-stage small-cell lung cancer. About 200 adults in China will receive durvalumab and be followed to see how long their cancer stays under control. The goal is to understand how well this treatment works in everyday medical practice.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIMITED-STAGE SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Research Site

    RECRUITING

    Beijing, China

  • Research Site

    RECRUITING

    Cangzhou, China

  • Research Site

    RECRUITING

    Dongguan, China

  • Research Site

    RECRUITING

    Fuzhou, China

  • Research Site

    RECRUITING

    Guangzhou, China

  • Research Site

    RECRUITING

    Huzhou, China

  • Research Site

    RECRUITING

    Jinan, 250117, China

  • Research Site

    RECRUITING

    Jinan, China

  • Research Site

    RECRUITING

    Nanjing, China

  • Research Site

    RECRUITING

    Nanning, China

  • Research Site

    RECRUITING

    Ningbo, China

  • Research Site

    RECRUITING

    Shanghai, China

  • Research Site

    RECRUITING

    Shenyang, China

  • Research Site

    RECRUITING

    Shijiazhuang, China

  • Research Site

    RECRUITING

    Taiyuan, China

  • Research Site

    RECRUITING

    Tianjing, China

  • Research Site

    TERMINATED

    Tianjing, China

  • Research Site

    RECRUITING

    Wuhan, China

  • Research Site

    RECRUITING

    Wuxi, China

  • Research Site

    RECRUITING

    Yangzhou, China

  • Research Site

    RECRUITING

    Zhengzhou, China

Conditions

Explore the condition pages connected to this study.